Kimberly C Paul1, Jessica Schulz2, Jeff M Bronstein3, Christina M Lill2, Beate R Ritz1,3. 1. Department of Epidemiology, UCLA (University of California, Los Angeles) Fielding School of Public Health. 2. Genetic and Molecular Epidemiology Group, Institute of Neurogenetics, University of Lübeck, Lübeck, Germany. 3. Department of Neurology, UCLA David Geffen School of Medicine.
Abstract
Importance: Genetic factors have a well-known influence on Parkinson disease (PD) susceptibility. The largest genome-wide association study (GWAS) identified 26 independent single-nucleotide polymorphisms (SNPs) associated with PD risk. Among patients, the course and severity of symptom progression is variable, and little is known about the potential association of genetic factors with phenotypic variance. Objective: To assess whether GWAS-identified PD risk SNPs also have a cumulative association with the progression of cognitive and motor symptoms in patients with PD. Design, Setting, and Participants: This longitudinal population-based cohort study of 285 patients of European ancestry with incident PD genotyped 23 GWAS SNPs. One hundred ninety-nine patients were followed up for a mean (SD) of 5.3 (2.1) years for progression (baseline: June 1, 2001, through November 31, 2007; follow-up: June 1, 2007, through August 31, 2013, with mortality surveillance through December 31, 2016); 57 patients had died or were too ill for follow-up, and 29 withdrew or could not be contacted. Movement disorder specialists repeatedly assessed PD symptom progression. Main Outcomes Measures: The combined association of PD risk loci, after creating a weighted polygenic risk score (PRS), with cognitive decline, motor progression, and survival, relying on Cox proportional hazards regression models and inverse probability weights to account for censoring. Results: Of the 285 patients undergoing genotyping, 160 were men (56.1%) and 125 were women (43.9%); the mean (SD) age at diagnosis was 69.1 (10.4) years. The weighted PRS was associated with significantly faster cognitive decline, measured by change in the Mini-Mental State Examination (hazard ratio [HR] per 1 SD, 1.44; 95% CI, 1.00-2.07). The PRS was also associated with faster motor decline, measured by time to Hoehn & Yahr Scale stage 3 (HR, 1.34; 95% CI, 1.00-1.79) and change in Unified Parkinson's Disease Rating Scale part III score (HR, 1.42; 95% CI, 1.00-2.01). Conclusions and Relevance: Susceptibility SNPs for PD combined with a cumulative PRS were associated with faster motor and cognitive decline in patients. Thus, these genetic markers may be associated with not only PD susceptibility but also disease progression in multiple domains.
Importance: Genetic factors have a well-known influence on Parkinson disease (PD) susceptibility. The largest genome-wide association study (GWAS) identified 26 independent single-nucleotide polymorphisms (SNPs) associated with PD risk. Among patients, the course and severity of symptom progression is variable, and little is known about the potential association of genetic factors with phenotypic variance. Objective: To assess whether GWAS-identified PD risk SNPs also have a cumulative association with the progression of cognitive and motor symptoms in patients with PD. Design, Setting, and Participants: This longitudinal population-based cohort study of 285 patients of European ancestry with incident PD genotyped 23 GWAS SNPs. One hundred ninety-nine patients were followed up for a mean (SD) of 5.3 (2.1) years for progression (baseline: June 1, 2001, through November 31, 2007; follow-up: June 1, 2007, through August 31, 2013, with mortality surveillance through December 31, 2016); 57 patients had died or were too ill for follow-up, and 29 withdrew or could not be contacted. Movement disorder specialists repeatedly assessed PD symptom progression. Main Outcomes Measures: The combined association of PD risk loci, after creating a weighted polygenic risk score (PRS), with cognitive decline, motor progression, and survival, relying on Cox proportional hazards regression models and inverse probability weights to account for censoring. Results: Of the 285 patients undergoing genotyping, 160 were men (56.1%) and 125 were women (43.9%); the mean (SD) age at diagnosis was 69.1 (10.4) years. The weighted PRS was associated with significantly faster cognitive decline, measured by change in the Mini-Mental State Examination (hazard ratio [HR] per 1 SD, 1.44; 95% CI, 1.00-2.07). The PRS was also associated with faster motor decline, measured by time to Hoehn & Yahr Scale stage 3 (HR, 1.34; 95% CI, 1.00-1.79) and change in Unified Parkinson's Disease Rating Scale part III score (HR, 1.42; 95% CI, 1.00-2.01). Conclusions and Relevance: Susceptibility SNPs for PD combined with a cumulative PRS were associated with faster motor and cognitive decline in patients. Thus, these genetic markers may be associated with not only PD susceptibility but also disease progression in multiple domains.
Authors: Ignacio F Mata; James B Leverenz; Daniel Weintraub; John Q Trojanowski; Alice Chen-Plotkin; Vivianna M Van Deerlin; Beate Ritz; Rebecca Rausch; Stewart A Factor; Cathy Wood-Siverio; Joseph F Quinn; Kathryn A Chung; Amie L Peterson-Hiller; Jennifer G Goldman; Glenn T Stebbins; Bryan Bernard; Alberto J Espay; Fredy J Revilla; Johnna Devoto; Liana S Rosenthal; Ted M Dawson; Marilyn S Albert; Debby Tsuang; Haley Huston; Dora Yearout; Shu-Ching Hu; Brenna A Cholerton; Thomas J Montine; Karen L Edwards; Cyrus P Zabetian Journal: Mov Disord Date: 2015-08-21 Impact factor: 10.338
Authors: Christina M Lill; Johnni Hansen; Jørgen H Olsen; Harald Binder; Beate Ritz; Lars Bertram Journal: Mov Disord Date: 2015-04-25 Impact factor: 10.338
Authors: Albert A Davis; Kristin M Andruska; Bruno A Benitez; Brad A Racette; Joel S Perlmutter; Carlos Cruchaga Journal: Neurobiol Aging Date: 2015-09-30 Impact factor: 4.673
Authors: Mike A Nalls; Nathan Pankratz; Christina M Lill; Chuong B Do; Dena G Hernandez; Mohamad Saad; Anita L DeStefano; Eleanna Kara; Jose Bras; Manu Sharma; Claudia Schulte; Margaux F Keller; Sampath Arepalli; Christopher Letson; Connor Edsall; Hreinn Stefansson; Xinmin Liu; Hannah Pliner; Joseph H Lee; Rong Cheng; M Arfan Ikram; John P A Ioannidis; Georgios M Hadjigeorgiou; Joshua C Bis; Maria Martinez; Joel S Perlmutter; Alison Goate; Karen Marder; Brian Fiske; Margaret Sutherland; Georgia Xiromerisiou; Richard H Myers; Lorraine N Clark; Kari Stefansson; John A Hardy; Peter Heutink; Honglei Chen; Nicholas W Wood; Henry Houlden; Haydeh Payami; Alexis Brice; William K Scott; Thomas Gasser; Lars Bertram; Nicholas Eriksson; Tatiana Foroud; Andrew B Singleton Journal: Nat Genet Date: 2014-07-27 Impact factor: 38.330
Authors: Yu-Hsuan Chuang; Ake T Lu; Kimberly C Paul; Aline D Folle; Jeff M Bronstein; Yvette Bordelon; Steve Horvath; Beate Ritz Journal: J Parkinsons Dis Date: 2019 Impact factor: 5.568
Authors: Junchao Shen; Noor Amari; Rebecca Zack; R Tyler Skrinak; Travis L Unger; Marijan Posavi; Thomas F Tropea; Sharon X Xie; Vivianna M Van Deerlin; Richard B Dewey; Daniel Weintraub; John Q Trojanowski; Alice S Chen-Plotkin Journal: Ann Neurol Date: 2022-06-07 Impact factor: 11.274
Authors: Emily J Hill; Laurie A Robak; Rami Al-Ouran; Jennifer Deger; Jamie C Fong; Paul Jerrod Vandeventer; Emily Schulman; Sindhu Rao; Hiba Saade; Joseph M Savitt; Rainer von Coelln; Neeja Desai; Harshavardhan Doddapaneni; Sejal Salvi; Shannon Dugan-Perez; Donna M Muzny; Amy L McGuire; Zhandong Liu; Richard A Gibbs; Chad Shaw; Joseph Jankovic; Lisa M Shulman; Joshua M Shulman Journal: Neurol Genet Date: 2022-06-09
Authors: Daniela Berg; Per Borghammer; Seyed-Mohammad Fereshtehnejad; Sebastian Heinzel; Jacob Horsager; Eva Schaeffer; Ronald B Postuma Journal: Nat Rev Neurol Date: 2021-04-20 Impact factor: 42.937
Authors: Agni Orfanoudaki; Emma Chesley; Christian Cadisch; Barry Stein; Amre Nouh; Mark J Alberts; Dimitris Bertsimas Journal: PLoS One Date: 2020-05-21 Impact factor: 3.240
Authors: Young-Gun Lee; Seun Jeon; Sung Woo Kang; Mincheol Park; Kyoungwon Baik; Han Soo Yoo; Seok Jong Chung; Seong Ho Jeong; Jin Ho Jung; Phil Hyu Lee; Young Ho Sohn; Alan C Evans; Byoung Seok Ye Journal: Alzheimers Dement (Amst) Date: 2021-05-21